v3.26.1
Segment Reporting
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The Company has one reportable segment which is specialty pharmaceutical products. The Company's chief operating decision maker (“CODM”) is its chief executive officer. The CODM uses consolidated, single segment financial information for purposes of evaluating performance, planning and forecasting future period financial results, and allocating resources. The CODM assesses performance for the single segment and decides how to allocate resources based on net income or loss that also is reported on the consolidated statement of operations as net income or loss. The measure of segment assets is reported on the consolidated balance sheet as total assets.
The following table summarizes selected financial information of the Company’s single operating segment for the three months ended March 31, 2026 and 2025 .
Three months ended March 31, 2026
20262025
Net revenues$9,131,317 $11,713,055 
Costs and expenses:
Cost of products sold1,933,889 1,425,714 
Selling and marketing5,064,875 4,231,980 
Research and development1,458,436 1,295,076 
General and administrative2,554,475 2,463,008 
Amortization1,248,934 1,005,330 
Segment operating expenses12,260,609 10,421,108 
Operating income (loss)(3,129,292)1,291,947 
Interest income78,031 125,709 
Interest expense(85,839)(163,802)
Income (loss) before income taxes(3,137,100)1,253,854 
Income tax expense(3,871)(5,670)
Co-commercialization investment loss(146,080)— 
Net income (loss)$(3,287,051)$1,248,184